BIOVAXYS

BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY

MADISON, Wis., Nov. 20, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce that SpayVac for Wildlife, Inc.'s Madison, Wisconsin laboratory and production facility is now fully able to supply its cutting-edge contraceptive vaccines, including its well-established pZP vaccine ("SpayVac®") and its newest GnRH vaccine for commercial aquaculture and other species.

SpayVac® vaccines produced in the Madison facility ready for shipment for the EU feral horse project

The scaled-up production capacity will support wider SpayVac availability for field trials and market seeding studies, the production ramp-up in preparation for a SpayVac launch in the near future, as well as new antigen formulations tailored for diverse animal contraceptive needs. The ability to produce two different lines of vaccine is a significant advancement following SpayVac for Wildlife's recent announcement of completing the set-up of its Madison-based research and production facility. "Part of our use of proceeds from ongoing fundraising will be to further scale up so we can produce tens of thousands of vaccines," said SpayVac's CEO, Tom D'Orazio.

Recently, large-scale shipments were made by SpayVac for Wildlife to support a major feral horse population management project in Europe, underscoring their commitment to expanding animal population control efforts globally. This follows the production of vaccine for an immunocontraception project in Southeast Asia this past summer.

Ursula Bechert, DVM, PhD, SpayVac VP for Research and Development, shared, "We continue to build momentum with ongoing trials in collaboration with the U.S. government and the EU, as well as a prominent aquaculture genetics company, focusing on a potential alternative to induced triploidy, which results in sterility but leaves fish more susceptible to disease."

SpayVac® vaccines produced in the Madison facility ready for shipment for the EU feral horse project

SpayVac is based on a patented liposome-based antigen delivery platform technology, licensed from BioVaxys (https://www.biovaxys.com), which has demonstrated a robust and sustained immune response in several species. SpayVac for Wildlife's single-dose, multi-year vaccines will address the fertility-control needs in wildlife, agricultural production animals, and commercial aquaculture markets.

BioVaxys is also developing its own vaccines based on the patented liposome-based antigen delivery platform technology for multiple human indications in infectious disease, oncology, and allergy, with several programs in clinical development.

Kenneth Kovan, BioVaxys President & Chief Operating Officer, stated, "SpayVac for Wildlife, already a leader in developing breeding control, will leverage its scaled-up capacity to shorten the product-development cycle allowing them to further expand their pipeline using BioVaxys' technology platforms as engines for innovation with new products."

About SpayVac for Wildlife, Inc.

SpayVac for Wildlife, Inc., (https://spayvac.com/) based in Madison, Wisconsin, develops humane fertility-control vaccines for animals. SpayVac contraceptive vaccines are effective in a variety of species for multiple years with just a single injection. SpayVac is a combination of an active ingredient encapsulated in a proprietary lipid nanoparticle. For questions about this research or SpayVac in general, please email contact@spayvac.com.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a unique and differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© "neoantigen" tumor cell construct platform for refractive late-stage ovarian cancer.

BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed "James Passin"
James Passin, CEO
BioVaxys Technology Corp.
+1 740 358 0555

ON BEHALF OF THE BOARD

Signed "Dr. Ursula Bechert"
Dr. Ursula Bechert, VP Research & Development
SpayVac for Wildlife, Inc.
+1 877 510 6812

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Photo: https://mma.prnewswire.com/media/2562565/SpayVac_vaccines_ready_for_shipment.jpg
Logo: https://mma.prnewswire.com/media/2415135/5037552/BioVaxys_Technology_Corp_Logo.jpg

SOURCE BioVaxys Technology Corp.

%SEDAR: 00045617E

CO: BioVaxys Technology Corp.

CNW 05:00e 20-NOV-24